Optimized in vivo transfer of small interfering RNA targeting dermal tissue using in vivo surface electroporation

Molecular Therapy Nucleic Acids

Volumn 1, Issue 2, 2012, Pages e11-

  Broderick, Kate E ^a   Chan, Amy ^b   Lin, Feng ^a   Shen, Xuefei ^a   Kichaev, Gleb ^a   Khan, Amir S ^a   Aubin, Justin ^b   Zimmermann, Tracy S ^b   Sardesai, Niranjan Y ^a  

^a Inovio Pharmaceuticals   (United States)

^b ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

Dermal; DNA vaccine; Electroporation; Electrotransfer; Gene transfer; Plasmid DNA

Indexed keywords

EID: 84868365382     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.1     Document Type: Article

References (32)

1. Bumcrot, D, Manoharan, M, Koteliansky, V and Sah, DW (2006). RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719. (Pubitemid 44764213)
2. de Fougerolles, A, Vornlocher, HP, Maraganore, J and Lieberman, J (2007). Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6: 443-453. (Pubitemid 47064567)
3. Akinc, A, Querbes, W, De, S, Qin, J, Frank-Kamenetsky, M, Jayaprakash, KN et al. (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligandbased mechanisms. Mol Ther 18: 1357-1364.
4. Higuchi, Y, Kawakami, S and Hashida, M (2010). Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs 24: 195-205.
5. Low, L, Mander, A, McCann, K, Dearnaley, D, Tjelle, T, Mathiesen, I et al. (2009). DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 20: 1269-1278.
6. Sallberg, M, Frelin, L, Diepolder, HM, Jung, MC, Mathiesen, I, Fons, M et al. (2010). Therapeutic vaccination followed by standard-of-care therapy in patients with chronic hepatitis C: a rapid clearance of viremia. Mol Ther 18: S110.
7. Yan, J, Pankhong, P, Shen, X, Giffer, M, Lee, J, Harris, D et al. (2010). Phase I safety and immunogenicity of HPV 16 and 18 DNA vaccines delivered via electroporation. Mol Ther 18: S184.
8. Hirao, LA, Wu, L, Khan, AS, Satishchandran, A, Draghia-Akli, R and Weiner, DB (2008). Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 26: 440-448.
9. Wallace, M, Evans, B, Woods, S, Mogg, R, Zhang, L, Finnefrock, AC et al. (2009). Tolerability of two sequential electroporation treatments using MedPulser DNA delivery system (DDS) in healthy adults. Mol Ther 17: 922-928.
10. Draghia-Akli, R, Khan, AS, Brown, PA, Pope, MA, Wu, L, Hirao, L et al. (2008). Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models. Vaccine 26: 5230-5237.
11. Laddy, DJ, Yan, J, Khan, AS, Andersen, H, Cohn, A, Greenhouse, J et al. (2009). Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 83: 4624-4630.
12. Patel, V, Valentin, A, Kulkarni, V, Rosati, M, Bergamaschi, C, Jalah, R et al. (2010). Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine 28: 4827-4836.
13. Frelin, L, Brass, A, Ahlén, G, Brenndörfer, ED, Chen, M and Sällberg, M (2010). Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans? Drug News Perspect 23: 647-653.
14. Bagarazzi, M, Yan, J, Shen, X, Giffear, M, Lee, J, Khans, A et al. (2010) Immunotherapy of post-LEEP CIN2/3 with HPV 16 and 18 E6/E7 DNA vaccines/electroporation. 50th ICAAC Boston, poster G1-202, 12-15 September 2010.
15. Ottensmeier, CH, Low, L, Mander, A, Tjelle, T, Campos-perez, J, Williams, T, et al. (2008). DNA fusion gene vaccination, delivered with or without in vivo electroporation: a potent and safe strategy for inducing antitumor immune response in prostate cancer. AACR Meeting Abstract: 2843.
16. Hao, J, Li, SK, Liu, CY and Kao, WW (2009). Electrically assisted delivery of macromolecules into the corneal epithelium. Exp Eye Res 89: 934-941.
17. Nakai, N, Kishida, T, Hartmann, G, Katoh, N, Imanishi, J, Kishimoto, S et al. (2010). Mitf silencing cooperates with IL-12 gene transfer to inhibit melanoma in mice. Int Immunopharmacol 10: 540-545.
18. Golzio, M, Mazzolini, L, Paganin-Gioanni, A and Teissié, J (2009). Targeted gene silencing into solid tumors with electrically mediated siRNA delivery. Methods Mol Biol 555: 15-27.
19. Dharmapuri, S, Aurisicchio, L, Biondo, A, Welsh, N, Ciliberto, G and La Monica, N (2009). Antiapoptotic small interfering RNA as potent adjuvant of DNA vaccination in a mouse mammary tumor model. Hum Gene Ther 20: 589-597.
20. Nakagawa, S, Arai, Y, Mori, H, Matsushita, Y, Kubo, T and Nakanishi, T (2009). Small interfering RNA targeting CD81 ameliorated arthritis in rats. Biochem Biophys Res Commun 388: 467-472.
21. Takayama, K, Suzuki, A, Manaka, T, Taguchi, S, Hashimoto, Y, Imai, Y et al. (2009). RNA interference for noggin enhances the biological activity of bone morphogenetic proteins in vivo and in vitro. J Bone Miner Metab 27: 402-411.
22. Molotkov, DA, Yukin, AY, Afzalov, RA and Khiroug, LS (2010). Gene delivery to postnatal rat brain by non-ventricular plasmid injection and electroporation. J Vis Exp (43).
23. Inoue, T, Sugimoto, M, Sakurai, T, Saito, R, Futaki, N, Hashimoto, Y et al. (2007). Modulation of scratching behavior by silencing an endogenous cyclooxygenase-1 gene in the skin through the administration of siRNA. J Gene Med 9: 994-1001. (Pubitemid 350104414)
24. Vologodskii, AV, Levene, SD, Klenin, KV, Frank-Kamenetskii, M and Cozzarelli, NR (1992). Conformational and thermodynamic properties of supercoiled DNA. J Mol Biol 227: 1224-1243.
25. Broderick, KE, Shen, X, Soderholm, J, Lin, F, McCoy, J, Khan, AS et al. (2011). Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther 18: 258-265.
26. Kaiser, PK, Symons, RC, Shah, SM, Quinlan, EJ, Tabandeh, H, Do, DV et al. (2010). RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol 150: 33-39.e2.
27. Davis, ME, Zuckerman, JE, Choi, CH, Seligson, D, Tolcher, A, Alabi, CA et al. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464: 1067-1070.
28. Broderick, KE, Kardos, T, McCoy, JR, Fons, MP, Kemmerrer, S and Sardesai, NY (2011). Piezoelectric permeabilization of mammalian dermal tissue for in vivo DNA delivery leads to enhanced protein expression and increased immunogenicity. Hum Vaccin 7 (suppl.): 22-28.
29. Lin, F, Shen, X, McCoy, JR, Mendoza, JM, Yan, J, Kemmerrer, SV et al. (2011). A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine 29: 6771-6780.
30. Rabussay, D (2008). Applicator and electrode design for in vivo DNA delivery by electroporation. Methods Mol Biol 423: 35-59.
31. Tjelle, TE, Rabussay, D, Ottensmeier, C, Mathiesen, I and Kjeken, R (2008). Taking electroporation- based delivery of DNA vaccination into humans: a generic clinical protocol. Met hods Mol Biol 423: 497-507.
32. Contag, CH and Bachmann, MH (2002). Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 4: 235-260. (Pubitemid 35217421)